<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/ct2/show/NCT02978521</url>
  </required_header>
  <id_info>
    <org_study_id>016/028/ICI</org_study_id>
    <nct_id>NCT02978521</nct_id>
  </id_info>
  <brief_title>Pulmonary Rehabilitation in Advanced Non-small Cell Lung Cancer Patients</brief_title>
  <official_title>Effect of a Pulmonary Rehabilitation Program on Skeletal Muscle Mass, Pulmonary Function, Inflammatory Response and Overall Survival on Patients Diagnosed With Non-small-cell Advanced Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Instituto Nacional de Cancerologia de Mexico</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Instituto Nacional de Cancerologia de Mexico</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Lung cancer (LC) is usually diagnosed in advanced stages and continues to be the leading&#xD;
      cause of cancer related deaths worldwide. Cancer cachexia are frequent among patients with LC&#xD;
      affecting up to 80% of patients with advanced stage disease, and it has been related with&#xD;
      higher risk of complications, length of hospital stay, and worst overall survival. During&#xD;
      cancer cachexia, both muscle and fat mass can be wasted, however, the loss of muscle mass has&#xD;
      been associated to higher treatment related toxicity, loss of functional status, shorter&#xD;
      progression free survival and overall survival in different types of cancer under various&#xD;
      treatments. Hence, preservation of muscle mass and function should be an important focus of&#xD;
      the multidisciplinary treatment of patients with LC.&#xD;
&#xD;
      Pulmonary rehabilitation (PR) has been known to improve pulmonary function, reduce fatigue&#xD;
      and improve exercise tolerance in patients with LC undergoing curative surgery. However, few&#xD;
      studies have focused on the efficacy of PR on patients with advanced cancer undergoing&#xD;
      palliative care with chemotherapy or targeted therapies.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The main objective of this study is to determine the effects of a pulmonary rehabilitation&#xD;
      program on the pulmonary function and muscle mass. Moreover, the effects on exercise&#xD;
      tolerance, inflammatory response, quality of live and overall survival will be explored.&#xD;
&#xD;
      Patients will be randomized into intervention group (IG) or control group (CG). Patients in&#xD;
      the IG will be scheduled to receive 12 sessions of PR over a period of 4-6 weeks (2-3&#xD;
      session/week). CG will receive information and recommendations on physical activity. Both&#xD;
      groups will receive nutritional assessment and intervention as needed.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>August 2016</start_date>
  <completion_date type="Anticipated">October 2018</completion_date>
  <primary_completion_date type="Anticipated">August 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pulmonary function</measure>
    <time_frame>After 12 sessions (6 weeks)</time_frame>
    <description>Pulmonary function Maximal expiratory and inspiratory pressure units: cm H2O (measured with Jaeger spirometer)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Muscle mass</measure>
    <time_frame>After 12 sessions (6 weeks)</time_frame>
    <description>Muscle mass measured by body composition analysis of CT images using lumbar vertebra 3 (L3)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inflammatory response</measure>
    <time_frame>After 12 sessions (6 weeks)</time_frame>
    <description>Quantification of: Interleukin (IL)-8, IL-1β, IL-6, IL-10, IL-12 and tumor necrosis factor (TNF) (Human Inflammatory Cytokine Kit Becton, Dickinson and Company (BD)™ Cytometric Bead Array) Units: pg/ml</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Exercise tolerance</measure>
    <time_frame>After 12 sessions (6 weeks)</time_frame>
    <description>6 minute walk test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life</measure>
    <time_frame>After 12 sessions (6 weeks)</time_frame>
    <description>Application of the &quot;european organization for research and treatment of cancer quality of life questionnaire (QLQ)-C30</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lung Cancer Quality of Life</measure>
    <time_frame>After 12 sessions (6 weeks)</time_frame>
    <description>Application of the &quot;european organization for research and treatment of cancer quality of life questionnaire (QLQ)LC-13&quot;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anxiety and Depression</measure>
    <time_frame>After 12 sessions (6 weeks)</time_frame>
    <description>Hospital Anxiety and Depression Scale (HADS</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">94</enrollment>
  <condition>Pulmonary Rehabilitation</condition>
  <condition>Sarcopenia</condition>
  <condition>Quality of Life</condition>
  <arm_group>
    <arm_group_label>Intervention Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients in the IG will be scheduled to receive Pulmonary Rehabilitation:&#xD;
12 sessions (60 minutes approximately) over a period of 4-6 weeks (2-3 session/week). Sessions will progress as patients tolerance to exercise and will include breathing techniques, resistance training on ergometer and treadmill.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>CG will receive information and recommendations on physical activity</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Pulmonary rehabilitation</intervention_name>
    <description>Session 1: ventilatory pattern training Session 2,3: ventilatory pattern + respiratory training with incentive spirometer Session 4-6: Sessions 1-3 training continues + training with Positive expiratory pressure device (Threshold PEP) and breathing trainer Threshold IMT) Sessions 7-9: Continue respiratory training + resistance training with RECK MOTOmed2 ergometer at a 30% intensity until 60% is achieved Session 10-12: Continue with previous training + treadmill training</description>
    <arm_group_label>Intervention Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Confirmed diagnosis of advanced non-small-cell lung cancer&#xD;
&#xD;
          -  Good performance status (ECOG 0-1)&#xD;
&#xD;
          -  Life expectancy &gt;12 weeks&#xD;
&#xD;
          -  Eligible to receive treatment with chemotherapy or tyrosinkinase inhibitors&#xD;
&#xD;
          -  Recent electrocardiogram without evidence of arrythmia&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Symptomatic brain metastasis&#xD;
&#xD;
          -  Uncontrolled pain (Visual Analog Scale &gt;5)&#xD;
&#xD;
          -  Uncontrolled hypertension (&gt;140/100mmHg)&#xD;
&#xD;
          -  Practice of regular moderate to intense physical activity at least 3 day/week&#xD;
&#xD;
          -  Not residents of Mexico City or unable to attend to therapy sessions&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Oscar Arrieta</last_name>
    <role>Study Director</role>
    <affiliation>Head of Thoracic Oncology Unit</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Oscar Arrieta</last_name>
    <phone>01 55 56280400</phone>
    <phone_ext>71113</phone_ext>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Diana Flores</last_name>
    <phone>01 55 56280400</phone>
    <phone_ext>71113</phone_ext>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Instituto Nacional de Cancerología</name>
      <address>
        <city>Mexico Distrito Federal</city>
        <zip>14080</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Oscar Arrieta, M.D.; M.Sc</last_name>
      <phone>01 55 56280400</phone>
      <phone_ext>71113</phone_ext>
    </contact>
    <contact_backup>
      <last_name>Diana Flores</last_name>
      <phone>01 55 56280400</phone>
      <phone_ext>71113</phone_ext>
    </contact_backup>
    <investigator>
      <last_name>Martha de la Torre, M. Sc</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Julissa Luvián, M. Sc</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Richard Alcantar, PT</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Karina Gallo, PT</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <reference>
    <citation>Bruera E. ABC of palliative care. Anorexia, cachexia, and nutrition. BMJ. 1997 Nov 8;315(7117):1219-22. doi: 10.1136/bmj.315.7117.1219. No abstract available.</citation>
    <PMID>9393230</PMID>
  </reference>
  <reference>
    <citation>Argiles JM, Alvarez B, Lopez-Soriano FJ. The metabolic basis of cancer cachexia. Med Res Rev. 1997 Sep;17(5):477-98. doi: 10.1002/(sici)1098-1128(199709)17:53.0.co;2-r. No abstract available.</citation>
    <PMID>9276862</PMID>
  </reference>
  <reference>
    <citation>Blum D, Omlin A, Baracos VE, Solheim TS, Tan BH, Stone P, Kaasa S, Fearon K, Strasser F; European Palliative Care Research Collaborative. Cancer cachexia: a systematic literature review of items and domains associated with involuntary weight loss in cancer. Crit Rev Oncol Hematol. 2011 Oct;80(1):114-44. doi: 10.1016/j.critrevonc.2010.10.004. Epub 2011 Jan 8.</citation>
    <PMID>21216616</PMID>
  </reference>
  <reference>
    <citation>Rhee CM, Kalantar-Zadeh K. Resistance exercise: an effective strategy to reverse muscle wasting in hemodialysis patients? J Cachexia Sarcopenia Muscle. 2014 Sep;5(3):177-80. doi: 10.1007/s13539-014-0160-z. Epub 2014 Aug 28.</citation>
    <PMID>25163460</PMID>
  </reference>
  <reference>
    <citation>Ozalevli S, Ilgin D, Kul Karaali H, Bulac S, Akkoclu A. The effect of in-patient chest physiotherapy in lung cancer patients. Support Care Cancer. 2010 Mar;18(3):351-8. doi: 10.1007/s00520-009-0659-6. Epub 2009 May 28.</citation>
    <PMID>19471973</PMID>
  </reference>
  <reference>
    <citation>Tarumi S, Yokomise H, Gotoh M, Kasai Y, Matsuura N, Chang SS, Go T. Pulmonary rehabilitation during induction chemoradiotherapy for lung cancer improves pulmonary function. J Thorac Cardiovasc Surg. 2015 Feb;149(2):569-73. doi: 10.1016/j.jtcvs.2014.09.123. Epub 2014 Oct 5.</citation>
    <PMID>25451483</PMID>
  </reference>
  <reference>
    <citation>Mourtzakis M, Prado CM, Lieffers JR, Reiman T, McCargar LJ, Baracos VE. A practical and precise approach to quantification of body composition in cancer patients using computed tomography images acquired during routine care. Appl Physiol Nutr Metab. 2008 Oct;33(5):997-1006. doi: 10.1139/H08-075.</citation>
    <PMID>18923576</PMID>
  </reference>
  <reference>
    <citation>Prado CM, Lieffers JR, McCargar LJ, Reiman T, Sawyer MB, Martin L, Baracos VE. Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: a population-based study. Lancet Oncol. 2008 Jul;9(7):629-35. doi: 10.1016/S1470-2045(08)70153-0. Epub 2008 Jun 6.</citation>
    <PMID>18539529</PMID>
  </reference>
  <reference>
    <citation>Degner LF, Sloan JA. Symptom distress in newly diagnosed ambulatory cancer patients and as a predictor of survival in lung cancer. J Pain Symptom Manage. 1995 Aug;10(6):423-31. doi: 10.1016/0885-3924(95)00056-5.</citation>
    <PMID>7561224</PMID>
  </reference>
  <reference>
    <citation>Stigt JA, Uil SM, van Riesen SJ, Simons FJ, Denekamp M, Shahin GM, Groen HJ. A randomized controlled trial of postthoracotomy pulmonary rehabilitation in patients with resectable lung cancer. J Thorac Oncol. 2013 Feb;8(2):214-21. doi: 10.1097/JTO.0b013e318279d52a.</citation>
    <PMID>23238118</PMID>
  </reference>
  <reference>
    <citation>Rivas-Perez H, Nana-Sinkam P. Integrating pulmonary rehabilitation into the multidisciplinary management of lung cancer: a review. Respir Med. 2015 Apr;109(4):437-42. doi: 10.1016/j.rmed.2015.01.001. Epub 2015 Jan 22.</citation>
    <PMID>25641113</PMID>
  </reference>
  <reference>
    <citation>Jastrzebski D, Maksymiak M, Kostorz S, Bezubka B, Osmanska I, Mlynczak T, Rutkowska A, Baczek Z, Ziora D, Kozielski J. Pulmonary Rehabilitation in Advanced Lung Cancer Patients During Chemotherapy. Adv Exp Med Biol. 2015;861:57-64. doi: 10.1007/5584_2015_134.</citation>
    <PMID>26017725</PMID>
  </reference>
  <reference>
    <citation>Henke CC, Cabri J, Fricke L, Pankow W, Kandilakis G, Feyer PC, de Wit M. Strength and endurance training in the treatment of lung cancer patients in stages IIIA/IIIB/IV. Support Care Cancer. 2014 Jan;22(1):95-101. doi: 10.1007/s00520-013-1925-1. Epub 2013 Sep 1.</citation>
    <PMID>23995813</PMID>
  </reference>
  <reference>
    <citation>Hwang CL, Yu CJ, Shih JY, Yang PC, Wu YT. Effects of exercise training on exercise capacity in patients with non-small cell lung cancer receiving targeted therapy. Support Care Cancer. 2012 Dec;20(12):3169-77. doi: 10.1007/s00520-012-1452-5. Epub 2012 Apr 14.</citation>
    <PMID>22526147</PMID>
  </reference>
  <verification_date>November 2016</verification_date>
  <study_first_submitted>November 18, 2016</study_first_submitted>
  <study_first_submitted_qc>November 28, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 1, 2016</study_first_posted>
  <last_update_submitted>November 28, 2016</last_update_submitted>
  <last_update_submitted_qc>November 28, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 1, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Instituto Nacional de Cancerologia de Mexico</investigator_affiliation>
    <investigator_full_name>Oscar Gerardo Arrieta Rodríguez MD</investigator_full_name>
    <investigator_title>Principal Investigator, Head of the Thoracic Oncology Unit</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sarcopenia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>


download date: ClinicalTrials.gov processed this data on September 20, 2023
link text: Link to the current ClinicalTrials.gov record.
url: https://clinicaltrials.gov/ct2/show/NCT02978521
org study id: 016/028/ICI
nct id: NCT02978521
lead sponsor: 
has dmc: Yes
Lung cancer (LC) is usually diagnosed in advanced stages and continues to be the leading
      cause of cancer related deaths worldwide. Cancer cachexia are frequent among patients with LC
      affecting up to 80% of patients with advanced stage disease, and it has been related with
      higher risk of complications, length of hospital stay, and worst overall survival. During
      cancer cachexia, both muscle and fat mass can be wasted, however, the loss of muscle mass has
      been associated to higher treatment related toxicity, loss of functional status, shorter
      progression free survival and overall survival in different types of cancer under various
      treatments. Hence, preservation of muscle mass and function should be an important focus of
      the multidisciplinary treatment of patients with LC.

      Pulmonary rehabilitation (PR) has been known to improve pulmonary function, reduce fatigue
      and improve exercise tolerance in patients with LC undergoing curative surgery. However, few
      studies have focused on the efficacy of PR on patients with advanced cancer undergoing
      palliative care with chemotherapy or targeted therapies.
The main objective of this study is to determine the effects of a pulmonary rehabilitation
      program on the pulmonary function and muscle mass. Moreover, the effects on exercise
      tolerance, inflammatory response, quality of live and overall survival will be explored.

      Patients will be randomized into intervention group (IG) or control group (CG). Patients in
      the IG will be scheduled to receive 12 sessions of PR over a period of 4-6 weeks (2-3
      session/week). CG will receive information and recommendations on physical activity. Both
      groups will receive nutritional assessment and intervention as needed.
allocation: Randomized
intervention model: Parallel Assignment
primary purpose: Supportive Care
masking: None (Open Label)
measure: Pulmonary function
time frame: After 12 sessions (6 weeks)
description: Pulmonary function Maximal expiratory and inspiratory pressure units: cm H2O (measured with Jaeger spirometer)
measure: Muscle mass
time frame: After 12 sessions (6 weeks)
description: Muscle mass measured by body composition analysis of CT images using lumbar vertebra 3 (L3)
measure: Inflammatory response
time frame: After 12 sessions (6 weeks)
description: Quantification of: Interleukin (IL)-8, IL-1β, IL-6, IL-10, IL-12 and tumor necrosis factor (TNF) (Human Inflammatory Cytokine Kit Becton, Dickinson and Company (BD)™ Cytometric Bead Array) Units: pg/ml
measure: Exercise tolerance
time frame: After 12 sessions (6 weeks)
description: 6 minute walk test
measure: Quality of Life
time frame: After 12 sessions (6 weeks)
description: Application of the "european organization for research and treatment of cancer quality of life questionnaire (QLQ)-C30
measure: Lung Cancer Quality of Life
time frame: After 12 sessions (6 weeks)
description: Application of the "european organization for research and treatment of cancer quality of life questionnaire (QLQ)LC-13"
measure: Anxiety and Depression
time frame: After 12 sessions (6 weeks)
description: Hospital Anxiety and Depression Scale (HADS
arm group label: Intervention Group
arm group type: Experimental
description: Patients in the IG will be scheduled to receive Pulmonary Rehabilitation:
12 sessions (60 minutes approximately) over a period of 4-6 weeks (2-3 session/week). Sessions will progress as patients tolerance to exercise and will include breathing techniques, resistance training on ergometer and treadmill.
arm group label: Control Group
arm group type: No Intervention
description: CG will receive information and recommendations on physical activity
intervention type: Other
intervention name: Pulmonary rehabilitation
description: Session 1: ventilatory pattern training Session 2,3: ventilatory pattern + respiratory training with incentive spirometer Session 4-6: Sessions 1-3 training continues + training with Positive expiratory pressure device (Threshold PEP) and breathing trainer Threshold IMT) Sessions 7-9: Continue respiratory training + resistance training with RECK MOTOmed2 ergometer at a 30% intensity until 60% is achieved Session 10-12: Continue with previous training + treadmill training
arm group label: Intervention Group
criteria: 
gender: All
minimum age: 18 Years
maximum age: 70 Years
healthy volunteers: No
last name: Oscar Arrieta
role: Study Director
affiliation: Head of Thoracic Oncology Unit
last name: Oscar Arrieta
phone: 01 55 56280400
phone ext: 71113
last name: Diana Flores
phone: 01 55 56280400
phone ext: 71113
facility: 
status: Recruiting
contact: 
contact backup: 
investigator: 
investigator: 
investigator: 
investigator: 
country: Mexico
citation: Bruera E. ABC of palliative care. Anorexia, cachexia, and nutrition. BMJ. 1997 Nov 8;315(7117):1219-22. doi: 10.1136/bmj.315.7117.1219. No abstract available.
PMID: 9393230
citation: Argiles JM, Alvarez B, Lopez-Soriano FJ. The metabolic basis of cancer cachexia. Med Res Rev. 1997 Sep;17(5):477-98. doi: 10.1002/(sici)1098-1128(199709)17:53.0.co;2-r. No abstract available.
PMID: 9276862
citation: Blum D, Omlin A, Baracos VE, Solheim TS, Tan BH, Stone P, Kaasa S, Fearon K, Strasser F; European Palliative Care Research Collaborative. Cancer cachexia: a systematic literature review of items and domains associated with involuntary weight loss in cancer. Crit Rev Oncol Hematol. 2011 Oct;80(1):114-44. doi: 10.1016/j.critrevonc.2010.10.004. Epub 2011 Jan 8.
PMID: 21216616
citation: Rhee CM, Kalantar-Zadeh K. Resistance exercise: an effective strategy to reverse muscle wasting in hemodialysis patients? J Cachexia Sarcopenia Muscle. 2014 Sep;5(3):177-80. doi: 10.1007/s13539-014-0160-z. Epub 2014 Aug 28.
PMID: 25163460
citation: Ozalevli S, Ilgin D, Kul Karaali H, Bulac S, Akkoclu A. The effect of in-patient chest physiotherapy in lung cancer patients. Support Care Cancer. 2010 Mar;18(3):351-8. doi: 10.1007/s00520-009-0659-6. Epub 2009 May 28.
PMID: 19471973
citation: Tarumi S, Yokomise H, Gotoh M, Kasai Y, Matsuura N, Chang SS, Go T. Pulmonary rehabilitation during induction chemoradiotherapy for lung cancer improves pulmonary function. J Thorac Cardiovasc Surg. 2015 Feb;149(2):569-73. doi: 10.1016/j.jtcvs.2014.09.123. Epub 2014 Oct 5.
PMID: 25451483
citation: Mourtzakis M, Prado CM, Lieffers JR, Reiman T, McCargar LJ, Baracos VE. A practical and precise approach to quantification of body composition in cancer patients using computed tomography images acquired during routine care. Appl Physiol Nutr Metab. 2008 Oct;33(5):997-1006. doi: 10.1139/H08-075.
PMID: 18923576
citation: Prado CM, Lieffers JR, McCargar LJ, Reiman T, Sawyer MB, Martin L, Baracos VE. Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: a population-based study. Lancet Oncol. 2008 Jul;9(7):629-35. doi: 10.1016/S1470-2045(08)70153-0. Epub 2008 Jun 6.
PMID: 18539529
citation: Degner LF, Sloan JA. Symptom distress in newly diagnosed ambulatory cancer patients and as a predictor of survival in lung cancer. J Pain Symptom Manage. 1995 Aug;10(6):423-31. doi: 10.1016/0885-3924(95)00056-5.
PMID: 7561224
citation: Stigt JA, Uil SM, van Riesen SJ, Simons FJ, Denekamp M, Shahin GM, Groen HJ. A randomized controlled trial of postthoracotomy pulmonary rehabilitation in patients with resectable lung cancer. J Thorac Oncol. 2013 Feb;8(2):214-21. doi: 10.1097/JTO.0b013e318279d52a.
PMID: 23238118
citation: Rivas-Perez H, Nana-Sinkam P. Integrating pulmonary rehabilitation into the multidisciplinary management of lung cancer: a review. Respir Med. 2015 Apr;109(4):437-42. doi: 10.1016/j.rmed.2015.01.001. Epub 2015 Jan 22.
PMID: 25641113
citation: Jastrzebski D, Maksymiak M, Kostorz S, Bezubka B, Osmanska I, Mlynczak T, Rutkowska A, Baczek Z, Ziora D, Kozielski J. Pulmonary Rehabilitation in Advanced Lung Cancer Patients During Chemotherapy. Adv Exp Med Biol. 2015;861:57-64. doi: 10.1007/5584_2015_134.
PMID: 26017725
citation: Henke CC, Cabri J, Fricke L, Pankow W, Kandilakis G, Feyer PC, de Wit M. Strength and endurance training in the treatment of lung cancer patients in stages IIIA/IIIB/IV. Support Care Cancer. 2014 Jan;22(1):95-101. doi: 10.1007/s00520-013-1925-1. Epub 2013 Sep 1.
PMID: 23995813
citation: Hwang CL, Yu CJ, Shih JY, Yang PC, Wu YT. Effects of exercise training on exercise capacity in patients with non-small cell lung cancer receiving targeted therapy. Support Care Cancer. 2012 Dec;20(12):3169-77. doi: 10.1007/s00520-012-1452-5. Epub 2012 Apr 14.
PMID: 22526147
responsible party type: Principal Investigator
investigator affiliation: Instituto Nacional de Cancerologia de Mexico
investigator full name: Oscar Gerardo Arrieta Rodríguez MD
investigator title: Principal Investigator, Head of the Thoracic Oncology Unit
mesh term: Sarcopenia
sharing ipd: Undecided